Key statistics
On Friday, Pharvaris NV (9EN:FRA) closed at 20.60, 51.47% above the 52 week low of 13.60 set on Nov 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.20 |
---|---|
High | 20.80 |
Low | 19.80 |
Bid | 20.60 |
Offer | 21.80 |
Previous close | 20.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 54.01m |
Free float | 32.77m |
P/E (TTM) | -- |
Market cap | 1.22bn USD |
EPS (TTM) | -2.56 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 20:55 GMT.
More ▼
- Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
- Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
- Pharvaris to Host Virtual Investor Event on October 23, 2024
- Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
- Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
- Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
- Pharvaris Presents Data at the Bradykinin Symposium 2024
- Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
- Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
- Pharvaris Announces Annual Meeting of Shareholders
More ▼